Weekly Research Analysts’ Ratings Updates for Impax Laboratories (IPXL)

Impax Laboratories (NASDAQ: IPXL) recently received a number of ratings updates from brokerages and research firms:

  • 3/14/2018 – Impax Laboratories was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 3/12/2018 – Impax Laboratories was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Impax missed estimates for both the counts in the fourth quarter of 2017. The company faces competition in the brand product market from Parkinson’s disease and CNS disorder focused large pharmaceutical companies. Impax’s Generics segment underperformed in 2017, due to significant pricing erosion complemented by erosion in volume. Moreover, the company’s manufacturing facilities have been hampered by quality control issues since 2011, which delayed Rytary’s approval. However, the company’s epinephrine auto-injector sales have picked up. Meanwhile, Impax is taking steps to reduce costs and improve efficiencies, which may save an estimated $130 million by the end of 2019. The merger with Amneal Pharma is a positive for Impax as it will have a diverse pipeline with more than 300 products under review or late stage development.”
  • 3/7/2018 – Impax Laboratories is now covered by analysts at SunTrust Banks, Inc.. They set a “buy” rating and a $24.00 price target on the stock.
  • 3/6/2018 – Impax Laboratories was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 3/2/2018 – Impax Laboratories was given a new $20.00 price target on by analysts at Royal Bank of Canada. They now have a “hold” rating on the stock.
  • 3/1/2018 – Impax Laboratories was given a new $21.00 price target on by analysts at Cowen Inc. They now have a “hold” rating on the stock.
  • 3/1/2018 – Impax Laboratories was given a new $19.00 price target on by analysts at Canaccord Genuity. They now have a “hold” rating on the stock.
  • 3/1/2018 – Impax Laboratories was given a new $35.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 2/24/2018 – Impax Laboratories was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 2/22/2018 – Impax Laboratories was given a new $19.00 price target on by analysts at Canaccord Genuity. They now have a “hold” rating on the stock.
  • 2/16/2018 – Impax Laboratories was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 2/8/2018 – Impax Laboratories was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 2/2/2018 – Impax Laboratories was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 1/26/2018 – Impax Laboratories was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 1/15/2018 – Impax Laboratories was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “Impax's epinephrine auto-injector sales have picked up and the company has 18 ANDAs pending FDA approval. Impax’s generics pipeline should be able to take advantage of the upcoming patent expirations amid competitive and pricing pressure, which is expected to persist through 2017. Meanwhile, Impax is taking steps to reduce costs and improve efficiencies, which may save an estimated $130 million by the end of 2019. The merger with Amneal Pharma is a positive for Impax as it will have a diverse pipeline with more than 300 products under review or late stage development. However, the company’s manufacturing facilities have been hampered by quality control issues since 2011, which delayed Rytary’s approval. Impax’s shares have outperformed the industry in the past one year. Estimates have remained stable ahead of the Q4 earnings results. The company has a mixed record of earnings surprises in recent quarters.”

Shares of Impax Laboratories Inc (NASDAQ:IPXL) traded up $0.25 during midday trading on Thursday, hitting $20.80. 1,146,982 shares of the company’s stock were exchanged, compared to its average volume of 1,011,704. Impax Laboratories Inc has a one year low of $8.80 and a one year high of $25.70. The company has a market capitalization of $1,534.18, a P/E ratio of -3.19, a PEG ratio of 0.88 and a beta of 1.01. The company has a debt-to-equity ratio of 4.11, a quick ratio of 1.52 and a current ratio of 1.96.

Impax Laboratories (NASDAQ:IPXL) last announced its earnings results on Thursday, March 1st. The specialty pharmaceutical company reported $0.11 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.01). Impax Laboratories had a positive return on equity of 10.42% and a negative net margin of 60.49%. The company had revenue of $182.90 million during the quarter, compared to the consensus estimate of $199.13 million. During the same period in the prior year, the firm posted $0.16 earnings per share. The company’s revenue was down 7.8% on a year-over-year basis. research analysts expect that Impax Laboratories Inc will post 1.27 earnings per share for the current year.

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Receive News & Ratings for Impax Laboratories Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply